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ABSTRACT 
Background: The current (2012) national cervical cancer screening 
guidelines seek to balance the benefits of cervical cancer prevention with the 
risks of harm that can occur as a result of over-screening. To minimize these 
risks, the guidelines recommend against cervical cancer screening in populations 
for whom risk of cervical cancer is low, defined as women <21 years of age, >65 
years of age, or post-hysterectomy. However, survey studies have demonstrated 
that healthcare providers have been resistant to decreasing cervical cancer 
screening, which may diminish reductions in harm sought by the current 
guidelines. 
Objectives: 1) To assess current Fairview Health Services and University 
of Minnesota Physicians healthcare provider adherence to the 2012 cervical 
cancer screening guidelines for women for whom screening is not recommended; 
and 2) To evaluate the effects of implementing improved clinical decision support 
functionality in the electronic health record to decrease cervical cancer screening 
in populations for whom screening is not recommended.  
Methods: A retrospective cross-sectional chart review was performed at Fairview 
Health Services and University of Minnesota Physicians to determine current 
screening practices from 2012-2014. Tests were designated as indicated or non-
indicated per the 2012 cervical cancer screening guidelines. Point estimates and 
descriptive statistics were calculated. Patient and provider characteristics were 
compared between indicated and non-indicated groups using chi-squared and 
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Wilcoxon Rank-sum tests. To test the effect of electronic health record clinical 
decision support, the proportion of guideline non-adherent Pap tests in women 
<21 or >65 years of age or post-hysterectomy were compared 4 months prior 
(April-August 2016) and 3 months after (August-October 2016) implementation of 
a decision support alert warning providers that a Pap test is not indicated. 
Providers could cancel the Pap test or override the alert and place the order. 
Provider characteristics and Pap test indications were summarized by pre- / post-
intervention period using descriptive statistics.  The ordering of non-indicated pap 
tests was compared by intervention period and provider level characteristics, 
using generalized estimating equation models. 
 Results: A total of 3,920 Pap tests were ordered from 2012-2014. A total 
of 257 (51%; 95% CI 46.1-54.9%) of tests in the <21 group, 536 (40%; 95% CI 
37.7-43.1%) in the >65 group and 605 (29%; 95% CI 27.1-31.0%) in the post-
hysterectomy group were not guideline adherent. Implementation of the clinical 
decision support alert did not change the proportion of guideline non-adherent 
Pap tests ordered (OR 1.08, 95% CI 0.77-1.52), and the proportion of cancelled 
Pap test orders was similar at each time period (20% pre-intervention vs. 21% 
post-intervention). 
Conclusions: For the populations of women for whom cervical cancer 
screening is not recommended, 35% of Pap tests performed in our health system 
were not guideline-adherent. An electronic health record clinical decision support 
alert did not change healthcare provider cervical cancer screening practices for 
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women who meet guideline criteria for screening cessation. This suggests that 
screening in these populations occurs for reasons other than lack of knowledge 
of the guidelines. 
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CHAPTER 1 
Single Health System Adherence to the 2012 Cervical Cancer 
Screening Guidelines at the Extremes of Age and Post-hysterectomy 
 
Introduction 
 In 2012 the American Society for Colposcopy and Cervical Pathology 
(ASCCP), American Society for Clinical Pathology (ASCP), American Cancer 
Society (ACS) and the United States Preventive Services Task Force (USPSTF) 
published unified cervical cancer screening guidelines which sought to minimize 
the harms of over-screening while maintaining adequate detection of treatable 
cervical cancer precursors [1, 2].  The guidelines recommended against 
screening in average-risk women younger than 21 years, older than 65 years of 
age provided adequate previous screening and no history of high-grade 
dysplasia in the past 20 years, and post-hysterectomy with the cervix removed 
and no history of high-grade dysplasia in the past 20 years. For women for whom 
screening is still recommended, the guidelines lengthened the screening interval 
for all age groups (Table 1.1). These guidelines were developed based on an 
extensive systematic evidence review, and were endorsed by the American 
College of Obstetrics and Gynecology (ACOG) [3]. 
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Table 1.1 2012 National Cervical Cancer Screening Guidelines 
Screening 
Population 
American Cancer Society, American Society of 
Colposcopy and Cervical Pathology, American Society 
of Clinical Pathologists, United States Preventive 
Services Task Force Recommendations1 
Age <21 years No screening 
Age 21-29 years Pap test alone (no HPV2 test) every 3 years 
Age 30-65 years Pap + HPV co-test every 5 years (recommended by 
American Cancer Society, American Society of Colposcopy 
and Clinical Pathology, American Society of Clinical 
Pathology) 
OR 
Pap test alone every 3 years (considered acceptable by 
American Cancer Society, American Society of Colposcopy 
and Clinical Pathology, American Society of Clinical 
Pathology) 
Age >65years No screening if: 
• Adequate prior screening (3 consecutive negative 
Pap tests or 2 consecutive negative HPV results 
within 10 years, most recent test within 5 years of 
age 65 years) 
• No history of high-grade dysplasia3 in the past 20 
years 
Post-hysterectomy No screening if: 
• Cervix removed 
• No history of high-grade dysplasia in the past 20 
years 
1 Recommendations apply only to average-risk women. Women who are immunocompromised or 
who were exposed to diethylstilbestrol require additional screening. 
2HPV, Human Papillomavirus 
3 High-grade dysplasia includes cervical intraepithelial neoplasia (CIN) 2 or 3, carcinoma in situ 
(CIS), and adenocarcinoma in situ (AIS) 
 
 Although cervical cancer screening guidelines have recommended against 
screening in women post-hysterectomy and age >65 years since 2003 and 
against screening in women <21 years since 2009, survey studies have shown 
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that a majority of women younger than age 21 years, older than age 65 years 
and post-hysterectomy continue to undergo cytology screening [4, 5]. While 
these self-reported high rates of continued screening are concerning, provider 
and patient surveys are only a proxy for true practice patterns. This study was 
performed to obtain a more objective measure of the rates of non-indicated 
cervical cancer screening at the extremes of age and post-hysterectomy. The 
primary objective of this study was to determine the guideline non-indicated 
screening Pap test rates in women younger than age 21 years (<21), older than 
age 65 years (>65) or post-hysterectomy in a single large health system. The 
secondary objectives of this study were to describe patient and provider 
characteristics associated with performance of a non-indicated Pap test in 
populations for whom the guidelines recommend against screening and to 
describe temporal trends during the study period. 
 
Methods 
 This retrospective cross-sectional study was approved by the University of 
Minnesota Institutional Review Board. The electronic health record was queried 
using Common Procedural Terminology (CPT) codes for all Pap tests performed 
between September 1, 2012 (6 months after publication of the American Society 
of Colposcopy and Cervical Pathology, American Society for Clinical Pathology 
and American Cancer Society guidelines) and August 31, 2014 within University 
of Minnesota Physicians and Fairview Health Services, a large nonprofit health 
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center in Minnesota which partners with 2,500 physicians and has over 56 
primary care clinics [6]. The health system includes academic and community 
clinics in urban, suburban and rural locations.  The dataset included the following 
information: 1) patient demographics: patient age at the time of Pap test, patient 
race; 2) Encounter information: clinic location and specialty; 3) Provider 
information: provider name and degree (Medical Doctor or Doctor of Osteopathy, 
Nurse Practitioner, Physician Assistant, Certified Nurse Midwife, other). The 
dataset was then further queried to identify the three following groups of patients: 
1) younger than 21 years of age (<21); 2) older than 65 years of age (>65); 3) 
post-hysterectomy. For patients undergoing more than one Pap test during the 
study period, only the first Pap test was included in the data analysis. A random 
number generator (www.randomizer.org/form.htm) was used to randomly select 
30% of charts within each of the three screening groups for a manual chart 
review. For each group, if >10% of reviewed Pap tests were categorized as 
indicated based on patient risk factors and/or previous Pap test results, then all 
charts in that group were manually reviewed.   
 For the manual chart reviews, encounter notes, previous Pap and Human 
Papillomavirus test results and patient medical and surgical histories were 
reviewed to determine the indication for the Pap test. For the <21 group, 
indicated reasons for Pap testing included: 1) immunosuppression, including 
transplant clearance; 2) follow-up of a previous abnormal Pap test; 3) age 21 
years within 6 months of Pap test.  Although screening women age 20.5 years is 
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not specifically indicated by the guidelines, we assumed that providers were 
providing necessary preventive healthcare due to worry that these women may 
not return to clinic for several years, and thus these Pap tests were analyzed as 
indicated. For the >65 group, indicated reasons for screening included: 1) history 
of high-grade dysplasia within the past 20 years; 2) inadequate previous 
screening (adequate previous screening defined per the guidelines as at least 
three documented normal Pap tests or two normal co-tests within the past 10 
years with at least one test within 5 years of age 65 years); 3) 
immunosuppression; 4) in-utero diethylstilbestrol exposure; 5) cancer 
surveillance (cervical, vulvar, vaginal, anal, endometrial, ovarian cancer 
surveillance). For the post-hysterectomy group, indicated screening included: 1) 
supracervical hysterectomy (a supracervical hysterectomy was assumed unless 
removal of the cervix was documented in the surgical history, clinic or operative 
notes or vaginal cytology was specified on the Pap order); 2) history of high-
grade dysplasia within the past 20 years; 3) immunosuppression; 4) 
diethylstilbestrol exposure; 5) cancer surveillance.  Although vaginal cytology is 
no longer recommended for endometrial cancer surveillance, it was not removed 
from the National Comprehensive Cancer Network surveillance guidelines until 
2015 and thus was categorized as indicated for the study period. During the 
study period national cancer surveillance guidelines did not recommend vaginal 
cytology for ovarian cancer surveillance, however, since this was recommended 
by most of the local gynecologic oncologists during the study period, Pap tests 
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performed for this reason were coded as indicated. For encounter notes detailing 
the reason for cervical cancer screening, the stated reason was used as the 
indication, unless a more guideline-adherent reason also existed. For example, if 
the clinic note documented that screening was performed in a woman >65 per 
patient request, but review of her labs and previous clinic notes did not document 
three normal Pap tests within 10 years, inadequate previous screening was listed 
as the indication for screening. For women <21 years of age who were 
presenting for prenatal care or their postpartum visit with no other indicated 
reason for Pap testing, “pregnancy” was listed as the reason for screening unless 
the patient was within  6 months of her 21st birthday. For charts in which the 
reason for Pap testing was not stated and an indicated reason was not 
discovered during chart review, “routine health maintenance” was assigned by 
the investigators as the indication for screening (Figure 1). 
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Figure 1. Flowchart describing the designation of Pap tests as indicated or non-indicated. 
Documented reasons were used unless a non-documented but indicated reason for a Pap test 
was discovered on chart review. Pap tests without a documented reason for which no guideline-
adherent indication was found were categorized as “routine health maintenance.” 
 
 Healthcare provider information, including gender and birthdate to 
calculate age in 2012, was obtained from the Minnesota Board of Medical 
Practice for physicians and physician assistants, and from the Minnesota Board 
of Nursing for nurse practitioners and certified nurse midwives.  The zip codes for 
the clinics were documented, and clinic locations were dichotomized as less than 
or greater than 60 miles from Minneapolis to serve as a surrogate for 
urban/suburban (<60 miles) or rural (>60 miles) clinics. 
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The primary objective of the study was to determine the proportion of non-
indicated screening Pap tests performed in women <21 and >65 years of age 
and post-hysterectomy. The secondary objectives were to describe patient and 
provider characteristics associated with screening in populations for whom the 
guidelines recommend against screening and to describe temporal trends during 
the study period.  Point estimates and exact 95% confidence intervals (CI) for the 
proportion of non-indicated Pap tests were calculated for each screening group. 
Differences in the proportion of non-indicated Pap tests were compared within 
each screening scenario by patient race and year of test using chi-squared tests 
and age using Wilcoxon Rank-Sum tests. Descriptive statistics for provider level 
data were calculated, and adherence to guidelines by provider level 
characteristics, including age, gender, degree, specialty, clinic location, and 
frequency of Pap orders (dichotomized as <1 Pap per week or 1+ Pap per week), 
was compared using general estimating equation models to account for repeated 
measures for some providers assuming an exchangeable correlation structure. 
Multivariate models were considered for each screening group including both 
patient and provider level characteristics identified as potentially relevant based 
on the univariate analyses, including variables with p-values <0.10.  Data were 
analyzed using SAS 9.4 (Cary, NC) and p-values <0.05 were considered 
statistically significant. 
 
Results 
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 Between September 1, 2012 and August 31, 2014, a total of 122,254 Pap 
tests were performed in 77,899 individual patients within the health system.  Pap 
tests were performed in a total of 3,920 women <21 and >65 and post-
hysterectomy (5% of the total population). During this time period, co-testing was 
not uniformly performed, but reflex Human Papillomavirus testing was performed 
as indicated per the American Society of Colposcopy and Cervical Pathology 
Management guidelines [7]; primary Human Papillomavirus testing was not 
performed during the study period. In the review of a random sample of 30% of 
the charts in each age group, 31% (n=62) in the <21, 51% (n=207) in the >65 
and 48% (n=506) in the post-hysterectomy group were guideline-indicated Pap 
tests. Therefore, all charts within each group were manually reviewed.  
 A total of 509 women under age 21 years (1% of all patients) underwent at 
least one Pap test during the study period. Of those, 257 (50.5%; 95% CI 46.1-
54.9%) of these Pap tests were not indicated per the 2012 guidelines; if patients 
within 6 months of their 21st birthdays had been coded as not indicated, then 
94% of Pap tests in this age group would have been non-indicated. The reasons 
for the non-indicated tests included routine health maintenance (66%), 
pregnancy (27%), and patient request (7%).  A majority of indicated Pap tests 
were performed in women who were within 6 months of their 21st birthday (89%), 
with a smaller number performed to follow-up abnormal Pap tests performed 
prior to 2012 (8%), due to immunocompromised status or transplant clearance 
(3%), or as a requirement to enroll in the military (0.4%). There was a difference 
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in median age between those for whom screening was indicated compared to 
those for whom screening was not indicated (p<0.0001), likely due to inclusion of 
all women within 6 months of their 21st birthday as indicated (Table 1.2).  Patients 
in this age group were seen by 219 providers; the median number of patients 
seen by each provider was 1 (range: 1-19).  Providers performing non-indicated 
Pap tests were more likely to be older (p=0.01), male (p=0.0005), and to perform 
Pap tests less than once per week (p=0.002).  Compared to physicians, nurse 
practitioners (p=0.05) and physician assistants (p=0.003) were less likely to 
perform non-indicated Pap tests. However, in multivariate analysis, only 
performing Pap tests less than once per week remained significant (p=0.003) 
(Table 1.2). 
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Table 1.2. Results for age <21 years group 
Patient characteristics 
 All  
(N=509) 
Pap Not Indicated 
(N=257) 
Pap Indicated 
(N=252) 
p-value1 
Patient Age, years 
   median (range) 
20 (14-20) 19 (14-20) 20 (18-20) <0.0001 
Race 
   n (%) 
   0.58 
African/African Am   54 (10.6)   31 (57.4)   23 (42.6)  
Am Indian/Alaskan     7   (1.4)     2 (28.6)     5 (71.4)  
Asian   16   (3.2)     6 (37.5)   10 (62.5)  
White 406 (79.8) 205 (50.5) 201 (49.5)  
No response   26   (5.1)   13 (50.0)   13 (50.0)  
Provider characteristics 
 Pap Not Indicated 
(N=257) 
Pap Indicated 
(N=252) 
Odds Ratio (95% CI) p-value2 
Provider Age, years 
   mean ±SD 
47.6±11.3 44.8±10.9 1.03 (1.01-1.05)3 0.01 
Gender n (%) n (%)   
Female 181 (45.6) 217 (54.5) 1.00  
Male   76 (68.5)   35 (31.5) 2.44 (1.48-4.03) 0.0005 
Provider Degree      
MD/DO 190 (57.6) 140 (42.4) 1.00  
NP   35 (41.7)   49 (58.3) 0.53 (0.29-0.99) 0.05 
CNM     5 (27.8)   13 (72.2) 0.40 (0.14-1.14) 0.09 
PAC   27 (35.1)   50 (64.9) 0.43 (0.24-0.75) 0.003 
Specialty     
Family Medicine 192 (52.2) 176 (47.8) 1.00  
Internal Medicine   19 (43.2)   25 (56.8) 0.67 (0.35-1.26) 0.21 
Obstetrics/Gynecology   43 (48.3)   46 (51.7) 0.72 (0.37-1.39) 0.32 
Other     3 (37.5)     5 (62.5) 0.50 (0.10-2.44) 0.39 
 
 
 
Clinic within 60 miles 
of Minneapolis 
    
Yes 236 (49.6) 240 (50.4) 1.00  
No   21 (63.6)   12 (36.4) 1.71 (0.69-4.24) 0.25 
Frequency of Pap 
Orders 
    
1+ Pap per week 194 (47.1) 218 (52.9) 1.00  
<1 Pap per week   63 (65.0)   34 (35.1) 2.20 (1.34-3.61) 0.002  
Multivariate Model2,4 
Provider age 1.02 (1.00-1.04)c 0.06 
Gender   
                                            Female 1.00  
                                            Male 1.28 (0.72-2.28) 0.40 
Provider Degree   
                                            MD/DO 1.00  
                                            NP     0.54 (0.28-1.03) 0.06 
                                            CNM 0.37 (0.13-1.07) 0.06 
                                            PAC 0.53 (0.28-1.00) 0.05 
Frequency of Pap Orders   
                                            1+ Pap per week            1.00  
                                            <1 Pap per week 2.27 (1.33-3.86) 0.003 
Abbreviations: Am, American; MD, Medical Doctor; DO, Doctor of Osteopathy; NP, Nurse Practitioner; CNM, Certified Nurse Midwife; PAC, 
Physician Assistant 
1Categorical variables: Fisher’s Exact test; continuous variables: Wilcoxon rank-sum test 
2General estimating equation model 
3Per 1 year increase in age 
4Adjusted for provider age, gender, degree, and frequency of Pap test orders; effective sample size: N=197. 
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A total of 1,327 women older than age 65 years (2% of all patients) 
underwent at least one Pap test during the study period.  Of these, 536 (40.4%; 
95% CI 37.7-43.1%) were not indicated. The most common reason for non-
indicated Pap tests was routine health maintenance (88%). Other reasons for 
non-indicated Pap tests were patient request (7%), follow-up of previous 
abnormal Pap tests for which the guidelines do not recommend follow-up (e.g. 
follow-up of an ASCUS Pap test 10 years prior with subsequent normal Pap 
tests; 5%), and history of high-grade cervical dysplasia more than 20 years prior 
with subsequent normal screening (0.6%).  The most common reasons for 
indicated cervical cancer screening in this age group were inadequate previous 
screening (56%), followed by guideline-adherent follow-up of an abnormal 
cervical cancer screening test (18%). Other reasons for indicated Pap testing 
were cancer surveillance (11%), evaluation of post-menopausal bleeding or 
abnormal exam findings (10%), high-grade dysplasia within the past 20 years 
(3%), immunocompromised state or transplant clearance (1%), diethylstilbestrol 
exposure (0.1%), and to meet a requirement for a research study (0.1%). In this 
group, white women were more likely to receive non-indicated screening 
(p=0.007) (Table 1.3). Patients in this age group were seen by 317 providers; the 
median number of patients seen by each provider was 2 (range: 1-52).  Providers 
performing non-indicated Pap tests in this group were more likely to be older 
(p=0.008), male (p=0.02), in specialties other than gynecology (p=0.04) and to 
work within 60 miles of Minneapolis (p=0.002). In multivariate analysis, male 
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gender (p=0.01), specialty (p=0.02) and clinic location (p=0.001) remained 
significant (Table 1.3).  
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Table 1.3. Results for age >65 years group 
Patient characteristics 
 All   
(N=1327) 
Pap Not Indicated 
(N=536) 
Pap Indicated 
(N=791) 
p-value1 
Patient Age, years 
   median (range) 
69 (65-95) 68 (66-88) 69 (65-95) 0.25 
Race 
   n (%) 
   0.007 
African/African Am     33   (2.5)     6 (18.2)   27   (81.8)  
Am Indian/Alaskan       5   (0.4)     0   (0.0)     5 (100.0)  
Asian     26   (2.0)     7 (26.9)   19  (73.1)  
White 1239 (93.4) 516 (41.7) 723  (58.4)  
No response     24   (1.8)     7 (29.2)   17  (70.8)  
Provider characteristics 
 Pap Not Indicated 
(N=536) 
Pap Indicated 
(N=791) 
Odds Ratio (95% CI) p-value2 
Provider Age, years 
   mean ±SD 
51.5±11.9 48.8±11.3 1.02 (1.00-1.03)3 0.008 
Gender     
Female 351 (37.5) 585 (62.5) 1.00  
Male 185 (47.3) 206 (52.7) 1.53 (1.07-2.18) 0.02 
Provider Degree     
MD/DO 476 (41.6) 669 (58.4) 1.00  
NP   40 (34.5)   76 (65.5) 0.76 (0.48-1.20) 0.24 
CNM     1   (9.1)   10 (90.9) 0.22 (0.03-1.75) 0.15 
PAC   19 (34.6)   36 (65.5) 0.90 (0.45-1.79) 0.76 
Specialty     
Family Medicine 334 (41.8) 466 (58.3) 1.00  
Internal Medicine   70 (42.2)   96 (57.8) 1.06 (0.67-1.68) 0.79 
Obstetrics/Gynecology 128 (37.1) 217 (62.9) 0.66 (0.44-0.99) 0.04 
     
 
 
 
 
Clinic within 60 miles 
of Minneapolis 
Yes 532 (42.8) 711 (57.2) 1.00  
No     4  (4.8)   80 (95.2) 0.13 (0.04-0.46) 0.002 
Frequency of Pap 
Orders 
    
1+ Pap per week 428 (41.2)  611 (58.8) 1.00  
<1 Pap per week 108 (37.5) 180 (62.5) 0.91 (0.65-1.29) 0.61 
Multivariate Model2,4 
Gender   
                            Female 1.00  
                            Male 1.73 (1.14-2.61) 0.01 
Specialty   
                           Family Medicine 1.00  
                           Internal Medicine 1.13 (0.68-1.85) 0.64 
                          Obstetrics/Gynecology 0.62 (0.42-0.92) 0.02 
Clinic Location   
                            <60 miles from Minneapolis 1.00  
                            >60 miles from Minneapolis 0.12 (0.03-0.44) 0.001 
Abbreviations: Am, American; MD, Medical Doctor; DO, Doctor of Osteopathy; NP, Nurse Practitioner;  
CNM,Certified Nurse Midwife; PAC, Physician Assistant 
1Categorical variables: Fisher’s Exact test; continuous variables: Wilcoxon rank-sum test 
2General estimating equation model 
3Per 1 year increase in age 
4Adjusted for provider age, gender, degree, and frequency of Pap test orders; effective sample size: N=290. 
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 A total of 2,084 women had at least one Pap test post-hysterectomy (3% 
of all patients).  Of these, 605 (29.0%; 95% CI 27.1-31.0%) were not indicated 
per the guidelines. The most common reason for non-indicated Pap tests was 
routine health maintenance (87%), with a much smaller proportion performed for 
non-indicated follow-up of abnormal Pap tests in the distant past (6%), patient 
request (4%), history of high-grade dysplasia more than 20 years prior (3%), and 
cancer surveillance in cancers without a Pap test indication, such as non-genital 
melanoma (0.7%).   The most common reasons for indicated Pap tests were 
cancer surveillance (45%) and supracervical hysterectomy (37%). Other 
indications were history of high-grade dysplasia within the past 20 years (11%), 
guideline-adherent follow-up of an abnormal Pap test (3%), evaluation of vaginal 
bleeding or an abnormal exam finding (3%), and diethylstilbestrol exposure, 
immunocompromised state or transplant clearance, patient request (each <1%).  
There were no differences patient characteristics between those who had 
indicated versus non-indicated testing (Table 1.4). Patients in this group were 
seen by 362 providers; the median number of patients seen by each provider 
was 3 (range: 1-122).  Gynecologists were less likely than primary care providers 
to order non-indicated Pap tests (p=0.003); no other provider characteristics were 
associated with the ordering of non-indicated tests (Table 1.4).   
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Table 1.4. Results for post-hysterectomy group 
Patient characteristics 
 All  
(N=2084) 
Pap Not Indicated  
(N=605) 
Pap Indicated 
(N=1479) 
p-value1 
Patient Age, years 
   median (range) 
54 (24-89) 55 (28-88) 54 (24-89) 0.12 
Race 
   n (%) 
   0.64 
African/African Am     95   (4.6)   31 (32.6)     64 (67.4)  
Am Indian/Alaskan     24   (1.2)     4 (16.7)     20 (83.3)  
Asian/Pacific Islander     40   (1.9)   13 (32.5)     27 (67.5)  
White 1854 (89.0) 539 (29.1) 1315 (70.9)  
No response     71   (3.4)   18 (25.4)     53 (74.7)  
Provider characteristics 
 Pap Not Indicated 
(N=605) 
Pap Indicated 
(N=1479) 
Odds Ratio (95% CI) p-value2 
Provider Age, years 
   mean ±SD 
47.2±11.7 45.8±10.5 1.00 (0.99-1.02)3 0.50 
Gender n (%) n (%)   
Female 449 (26.9) 1219 (73.1) 1.00  
Male 156 (37.5)   260 (62.5) 1.25 (0.89-1.74) 0.20 
Provider Degree     
MD/DO 433 (31.2)   953 (68.8) 1.00  
NP   91 (18.9)   391 (81.1) 1.16 (0.77-1.74) 0.49 
CNM     3 (18.8)     13 (81.3) 0.75 (0.18-3.10) 0.70 
PAC   78 (39.0)   122 (61.0) 1.35 (0.90-2.03) 0.15 
Specialty     
Family Medicine 397 (38.4) 638 (61.6) 1.00  
Internal Medicine   63 (37.1) 107 (62.9) 0.91 (0.60-1.39) 0.67 
Obstetrics/Gynecology 130 (28.6) 324 (71.4) 0.61 (0.44-0.85) 0.003 
Other   15 (3.5) 410 (96.5) 0.07 (0.04-0.15) <0.001 
 
 
 
Clinic within 60 miles 
of Minneapolis 
    
Yes 582 (28.9) 1435 (71.2) 1.00  
No   23 (34.3)     44 (65.7) 1.24 (0.64-2.40) 0.53 
Frequency of Pap 
Orders 
    
1+ Pap per week 513 (29.2) 1243 (70.8) 1.00  
<1 Pap per week   92 (28.1)   236 (72.0) 1.05 (0.76-1.44) 0.78 
Abbreviations: Am, American; MD, Medical Doctor; DO, Doctor of Osteopathy; NP, Nurse Practitioner; CNM, Certified Nurse Midwife; PAC, 
Physician Assistant 
1Categorical variables: Fisher’s Exact test; continuous variables: Wilcoxon rank-sum test 
2General estimating equation model 
3Per 1 year increase in age 
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 Between 2012 and 2014, the total number of Pap tests ordered per month 
decreased in all 3 groups. However, temporal trends in the proportion of non-
indicated Pap tests ordered each year varied by group. In the <21 group, there 
was a decline in the proportion of non-indicated Pap tests over the study time 
period (p=0.006). In contrast, there was an increase in the proportion of non-
indicated tests ordered in the post-hysterectomy group during the same time 
period (p=0.04). The proportion of non-indicated Pap tests in the >65 group 
remained relatively stable over time (p=0.91). 
 
Discussion 
 Cervical cancer screening at the extremes of age and post-hysterectomy 
was performed in 35% patients in our health system despite recommendations 
against screening for more than a decade.  The proportion of non-indicated Pap 
tests appeared to increase in the post-hysterectomy group despite a temporal 
decrease in the total number of Pap tests and a concomitant decrease in the 
proportion of non-indicated tests in the <21 years age group. There were no 
common patient or provider characteristics associated with excess screening 
across all groups. Non-indicated screening is likely due to confusion about the 
guidelines and patient and provider worry that omitting screening will increase 
the cervical cancer incidence. 
 Our results build on those of previous survey studies showing that women 
at low risk for developing cervical cancer continue to undergo screening. A 
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claims database study showed that 57% of women younger than age 21 years 
had Pap tests performed  [4], and a 2010 study using data from the National 
Health Interview Survey showed that 58.4% of women >65 years of age and 
34.1% of women post-hysterectomy continued Pap testing [5].  
 Lack of knowledge of the guidelines is one reason for non-adherence [8]. 
Unified guidelines were created in 2012 [1-3], but the guidelines are complex and 
have changed frequently [9, 10].  Our chart review showed that providers often 
did not differentiate between abnormal cytology and a histologic diagnosis of 
dysplasia. Furthermore, the coupling of Pap tests with prenatal care increased 
screening in women <21 years of age.  
Some providers distrust the guidelines. In a 2016 California survey, 35% 
of primary care and 59% of gynecologists did not feel that the current guidelines 
were clinically appropriate [11]; interestingly gynecologists had lower rates of 
non-indicated screening in our study . Some respondents to the California survey 
felt that the guidelines were created to save money and that decreasing 
screening would result in an increased incidence of cervical cancer. Other 
providers continue screening to meet patient expectations during health 
maintenance visits, and many providers do not have adequate time to explain the 
guideline changes to patients [11]. Lastly, some providers acknowledged 
financial incentive to continuing cervical cancer screening [11].  
In this study, the increase in the proportion of non-indicated Pap tests in 
the post-hysterectomy group may be due to a change in the total number of Pap 
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tests performed rather than a true increase in the performance of non-indicated 
tests. During the study period the total number of Pap tests performed in the 
post-hysterectomy group declined by 56% while the number of non-indicated Pap 
tests only decreased by 46%. This may reflect adoption of the guidelines by 
some while those who intentionally disregarded the guidelines continued to 
screen.   
 The strengths of this study are the large number of patients from a large 
health system which includes urban, suburban and rural sites and both academic 
and community clinics. All charts were manually reviewed; an electronic health 
record query alone would have inaccurately doubled the number of non-indicated 
Pap tests in women <21 and >65 years old, and tripled the number in post-
hysterectomy patients. Nonetheless, our study provides a conservative estimate 
of the number of non-indicated Pap tests, and the true number may be much 
higher.  The primary limitation of our study is the fact that we could only compare 
the number of non-indicated Pap tests to the total number of Pap tests performed 
within each screening group; ideally we would have compared the number of Pap 
tests performed to the total number of women seen within the health system in 
each group, however we were unable to query the data in this way. This study 
was performed within a single health system, so our results may not be 
generalizable to other health systems. Other limitations of the study are those 
inherent to a retrospective chart review.  Data collection was limited by the 
quality of documentation and we only had access to records within our electronic 
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health record  It is possible that patients had a Pap testing history outside of our 
system which likely resulted in an over-estimate in the number of women >65 
years of age who continued screening due to inadequate previous testing.                                                         
 The 2012 guidelines seek to maintain the benefits of screening while 
limiting potential harms, such as preterm delivery in future pregnancies following 
excisional procedures, increased risk of pelvic organ prolapse or urinary 
incontinence following hysterectomy, or vaginal stenosis following treatment of 
vaginal dysplasia [2]. Continued screening in populations at low risk for cervical 
cancer limits the protections sought by the current guidelines.  
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CHAPTER 2  
Effect of an Electronic Health Record Clinical Decision Support Alert to 
Decrease Cervical Cancer Screening in Women Beyond the Screening Age 
Limits or Post-hysterectomy 
Introduction 
Lack of knowledge of the complex guidelines is a major barrier to 
guideline adherence [8, 11]. Since 2009, the U.S. Department of Health and 
Human Services has promoted usage of electronic health system clinical 
decision support to encourage the practice of evidence-based medicine [12]. The 
objective of this study was to test the effect of an electronic health record (EHR) 
clinical decision support alert to decrease cervical cancer over-screening in 
women <21 or >65 years of age, or post-hysterectomy.  
 
Methods 
This quality improvement initiative and study were implemented at 
Fairview Health Systems and University of Minnesota Physicians. The University 
of Minnesota Medical Center is one division of Fairview Health System, a large 
non-profit health center in Minnesota. The Fairview Health System is composed 
of greater than 56 primary care clinics in urban, suburban, and rural locations [6]. 
University of Minnesota Physicians is the non-profit multi-specialty group practice 
for the University of Minnesota Medical School faculty, many of whom provide 
clinical services at the University of Minnesota Medical Center and other Fairview 
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Health System clinics [13].  University of Minnesota Physicians collaborates with 
Fairview Health System to provide care to patients throughout Minnesota. The 
groups share a common electronic health record (EHR), thus changes can be 
implemented at University of Minnesota Physician clinics and Fairview Health 
System Clinics simultaneously. Prior to this EHR intervention, there was no 
clinical decision support for cervical cancer screening in the system; clinical 
decision support was in place for other healthcare interventions.  
A Best Practice Alert (BPA) was designed by the study investigators in 
collaboration with several physician informaticists and information technology 
professionals. The alert was then reviewed and approved by the health system 
Clinical Decision Support and Ambulatory Informatics Committees. The BPA was 
implemented in the Epic EHR and deployed first in a pilot clinic to test 
acceptability, and subsequently deployed to all clinics within the healthcare 
system, including community and academic-based practice plan clinics (Fairview 
Health Services and University of Minnesota Physician, respectively). For 4 
months (January 19-May 17, 2016), the BPA fired silently in the background: the 
EHR tracked every time an order was entered for a screening Pap test in a 
woman <21 years of age, >65 years of age, or post-hysterectomy (provided the 
hysterectomy was documented in the surgical history universal field and thus 
identified by the EHR), but the EHR user would not see the alert. For the 
following 3 months (May 18-August 17, 2016) the BPA was live and actively 
working: the BPA was made visible to the user whenever a screening Pap test 
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was ordered for a woman <21 years of age, >65 years of age, or post-
hysterectomy. The BPA informed the user that screening Pap tests are not 
indicated in this group. The BPA linked to the American Society of Colposcopy 
and Cervical Pathology (ASCCP) guidelines for reference [2], and the provider 
was given 2 options: 1) cancel the Pap test order, or 2) override the BPA and 
order the Pap test. Providers who overrode the BPA were asked but not required 
to state a reason. Options included: 1) immunocompromised; 2) history of 
diethylstilbestrol exposure; 3) history of high-grade dysplasia; 4) follow-up of 
previous abnormal cervical cancer screening; 5) inadequate previous screening; 
6) cancer surveillance; 7) other. Two months prior to the BPA going live 
information about the BPA was included in the monthly health system newsletter. 
Additionally, the month the BPA went live an 8-minute webinar detailing the 
changes to the cervical cancer screening orders was sent to all health system 
providers for optional review. 
This study was designated a retrospective cohort study of a quality 
improvement intervention by the University of Minnesota IRB. Thus, 
implementation of the clinical decision support alert was considered IRB-exempt, 
but IRB approval was obtained for a retrospective data review. The effect of the 
BPA was measured by comparing cervical cancer screening practices in women 
<21 or >65, or post-hysterectomy before and after the BPA was visible to EHR 
users. An electronic health record analytics platform (Logicstream, Minneapolis, 
MN) captured each encounter when a guideline non-adherent test was ordered, 
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both during the pre-intervention and post-intervention periods. A manual chart 
review of all identified encounters was then performed to determine the reason 
for the Pap test, whether or not ordering was congruent with the 2012 cervical 
cancer screening guidelines and the action on the Pap test (i.e. continuation or 
cancellation of the order). For women >65 years of age whose chart review did 
not document adequate previous screening either through review of laboratory 
results or documentation in the provider’s note, the Pap test was coded as 
guideline-adherent due to inadequate previous screening. For women <21 years 
of age but within 6 months of their 21st birthday, Pap tests were coded as 
indicated. Pap tests for which we could find no guideline-adherent reason were 
coded as non-adherent, performed for “routine healthcare maintenance.” Pap 
test orders which were placed without a Pap specimen subsequently sent to 
cytology were coded as cancelled. To better understand workflow, the staff who 
entered the order (e.g. provider, nurse, medical assistant, other) as well as the 
encounter provider (physician, nurse practitioner, certified nurse midwife, 
physician assistant) were recorded. Healthcare provider data were collected from 
the Minnesota Board of Medical Practice and the Medical Board of Nursing to 
determine if provider gender or age in 2012 was associated with guideline 
adherence. Lastly, zip codes of the clinics were collected to determine if rural 
(defined as >30 miles outside of the Minneapolis-St. Paul metro area) or urban 
location was associated with guideline-adherence.  
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Provider characteristics and Pap test indications were summarized by pre- 
or post-intervention period using descriptive statistics.  The ordering of guideline 
non-adherent Pap tests was compared by intervention period and provider level 
characteristics, including age, gender, specialty, and clinic location using 
generalized estimating equation models to account for repeated measures for 
some providers assuming an exchangeable correlation structure.  Odds ratios 
and 95% confidence intervals are presented.  Analyses were conducted in SAS 
9.4 (Cary, NC) and p-values of <0.05 were considered statistically significant. 
Results 
In the pre-intervention period, there were 388 (average 97 per month) Pap 
tests ordered, compared to 313 (average 104 per month) Pap tests in the post-
intervention period. Of these, 240 (62%) were guideline non-adherent in the pre-
intervention period, and 198 (63%) were guideline non-adherent in the post-
intervention period. There were no differences in provider characteristics (age, 
gender, provider degree, specialty), staff who entered the order, or location of the 
clinic (Table 2.1). 
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Table 2.1. Provider characteristics 
 Pre-Intervention 
(N=388) 
Post-Intervention 
(N=313) 
 N Mean (SD) N Mean (SD) 
Provider Age, years 388 48.8 (12.9) 313 48.3 (13.1) 
     
 N (%) N (%) 
Provider Gender     
   Female 216 (55.7) 187 (59.7) 
   Male 172 (44.3) 126 (40.3) 
Provider Degree     
   MD/DO/MBBS 297 (76.6) 228 (72.8) 
   Nurse Practitioner   51 (13.1)   56 (17.9) 
   Certified Nurse Midwife     7 (  1.8)     4 (  1.3) 
  Physician Assistant   33 (  8.5)   25 (  8.0) 
Specialty     
   Family Medicine 141 (36.3)   97 (31.0) 
   Internal Medicine   37 (  9.5)   41 (13.1) 
   Gynecology 209 (53.9) 173 (55.3) 
   Pediatrics     0 (  0.0)     2 (  0.6) 
   Other     1 (  0.3)     0 (  0.0) 
Order Entered     
   Provider1 150 (38.7) 112 (35.8) 
   Medical Assistant 202 (52.1) 176 (56.2) 
   Nurse   35 (  9.0)   23 (  7.4) 
   Unknown     1 (  0.3)     2 (  0.6) 
Clinic within 30 miles of 
Minneapolis 
    
   Yes 340 (87.6) 288 (92.0) 
   No   48 (12.4)   25 (  8.0) 
Abbreviations:  MD, Doctor of Medicine; DO, Doctor of Osteopathic Medicine; MBBS, Bachelor of 
Medicine/Bachelor of Surgery. 
1Provider refers to physician, nurse practitioner, certified nurse midwife, or physician assistant of 
record for the encounter during which cervical cancer screening was performed. 
 
 
 Post-intervention, there was no difference in the proportion of non-
indicated Pap tests ordered in women <21 or >65 years of age, or post-
hysterectomy (OR 1.08, 95% CI 0.77-1.52) (Table 6). There was also no 
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difference in the proportion of guideline non-adherent Pap tests orders which 
were ultimately cancelled (pre-intervention 20% vs. 21%) either due to patient or 
provider decision not to order a test after an EHR order was placed, or due to 
placement of orders prior to the patient encounter with subsequent cancellation 
of the order if the patient did not present to her clinic visit. A majority (51% pre- 
and post-intervention) were ordered for routine healthcare maintenance. There 
were more Pap tests ordered in women >65 years of age due to inadequate 
previous screening post-intervention (16% vs. 8%), and more Pap tests ordered 
for surveillance following high-grade dysplasia pre-intervention (5% vs. 3%). 
Other reasons for ordering Pap tests are detailed in Table 2.2.  
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Table 2.2. BPA Trigger and Action 
 Pre-Intervention 
(N=388) 
Post-Intervention 
(N=313) 
 N (%) N (%) 
Reason for Trigger     
   <21 years   80 (20.6)   66 (21.1) 
   >65 years 196 (50.5) 170 (54.3) 
   >65 years+Post-hyst   68 (17.5)   52 (16.6) 
   Post-hyst   44 (11.3)   25 (  8.0) 
Pap was indicated     
   No 240 (61.9) 198 (63.3) 
   Yes 148 (38.1) 115 (36.7) 
Action Taken     
   Cancelled   77 (19.9)   64 (20.5) 
   Ordered 311 (80.2) 249 (79.6) 
Reason for Pap     
   21 in <6 months   46 (11.9)   26 (  8.3) 
   Abnormal exam   10 (  2.6)     1 (  0.3) 
   Cancer surveillance   20 (  5.2)   21 (  6.7) 
   Immunosuppressed     5 (  1.3)     3 (  1.0) 
   Inadequate screening1   32 (  8.3)   50 (16.0) 
   PMB   22 (  5.7)     7 (  2.2) 
   Patient Request   10 (  2.6)   16 (  5.1) 
   Pregnant     4 (  1.0)     2 (  0.6) 
   RHM 198 (51.0) 161 (51.4) 
   Supracervical hyst     5 (  1.3)     2 (  0.6) 
   Abnormal follow-up   12 (  3.1)   12 (  3.8) 
   History of CIN2+2   20 (  5.2)     9 (  2.9) 
   Other     4 (  1.0)     3 (  1.0) 
Abbreviations: BPA, Best Practice Alert; hyst, hysterectomy; PMB, postmenopausal bleeding; 
RHM, routine health maintenance 
1Inadequate screening is defined by lack of at least 3 normal Pap tests or 2 negative Human 
Papillomavirus (HPV) tests within 10 years of age 65 years, with at least 1 test within 5 years of 
age 65 years. 
2CIN2+ includes cervical intraepithelial neoplasia (CIN) grade 2 and 3, cervical carcinoma in situ 
(CIS), and adenocarcinoma in situ (AIS) 
 
Multivariate analysis of provider characteristics associated with the 
ordering of guideline non-adherent Pap tests showed that only male gender was 
statistically significant (OR 2.30, 95% CI 1.36-3.89) (Table 2.3). There were no 
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differences in the proportion of guideline non-adherent Pap tests by specialty or 
clinic location. 
 
Table 2.3. Multivariate Generalized Estimating Equation Model:  
Effect of BPA and provider characteristics associated with ordering a 
guideline non-adherent Pap test 
 Odds Ratio (95% CI)1 p-value1 
BPA Alert   
   No alert visualized 1.00  
   BPA alert visualized 1.08 (0.77, 1.52) 0.64 
Provider Age, per year increase 1.00 (0.98, 1.02) 0.76 
Provider Gender   
   Female 1.00  
   Male 2.30 (1.36, 3.89) 0.002 
Specialty   
   Internal Medicine 1.00  
   Family Medicine 0.98 (0.52, 1.87) 0.96 
   Gynecology 0.74 (0.38, 1.46) 0.39 
Clinic within 30 miles of Minneapolis   
   Yes 1.00  
   No 1.17 (0.58, 2.34) 0.66 
Abbreviations: BPA, Best Practice Alert 
1Excluded pediatrics or “other” specialty due to small numbers 
 
 Overall, half (52%) of the guideline non-adherent Pap tests were ordered 
by 11 providers. Of these, a single gynecology clinic and five providers were 
responsible for ordering 45% of the 198 guideline non-adherent Pap tests in the 
post-intervention period, with a single provider ordering 21% of the tests. The 
remaining 94 guideline non-adherent Pap tests were ordered by 77 providers, 
with 64 providers each ordering a single guideline non-adherent Pap test. 
 
Discussion 
32 
 
 
 
 Our study showed that an EHR clinical decision alert intended to decrease 
guideline non-adherent cervical cancer screening did not decrease screening in 
women beyond the screening age limits or post-hysterectomy. In contrast to the 
results of this study, a previous study of a similar electronic health record BPA to 
decrease guideline non-adherent screening in women <21 years of age showed 
a significant decrease in screening post-intervention [14]. The intervention in this 
study was implemented in 2011, two years after the guidelines recommended 
against screening in women <21 years of age regardless of age at sexual debut. 
At that time, a majority of over-screening may have occurred due to lack of 
knowledge of the guidelines. However, since our intervention was performed five 
years later, lack of knowledge may have been less of a factor. Providers also 
may be more likely to accept the guideline recommendation against screening in 
young women compared to older women, as was demonstrated in a study in 
2010 showing a BPA changed provider practices in women <21 years of age but 
did not significantly impact the ordering of guideline non-adherent Pap tests in 
women >70 years of age [15]. Although we did not see a difference post-
intervention in either group in our study, the number of tests ordered in women 
>65 years of age was more than double that of women <21 years of age in both 
the pre- and post-intervention periods.    
 Further review of our data revealed that a majority of guideline non-
adherent Pap tests were ordered by a few healthcare providers. The reasons for 
over-screening among these 11 providers needs to be explored further, but these 
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data suggest that a focused educational intervention addressing individual 
provider concerns or misconceptions about screening may be more effective 
than a system-wide EHR intervention. Furthermore, despite accounting for 
providers who ordered >1 Pap test during the study period, male providers were 
more than twice as likely to order Pap tests beyond the screening age limits or 
post-hysterectomy, and provider gender remained statistically significant when 
controlling for provider age. Studies of provider adherence to previous versions 
of the cervical cancer screening guidelines have shown mixed results [16, 17]. A 
previous study which showed female providers were more likely to adhere to 
cervical cancer screening recommendations in women younger than 21 years of 
age and 30+ years of age found that provider-reported interest in women’s health 
was a significant predictor of delaying screening in women younger than 21 
years of age but not in women 30+ years of age [17]. It is also possible that 
female providers see a higher proportion of female patients, resulting in greater 
awareness of the guidelines. However, our previous study evaluating cervical 
cancer screening practices within our health system showed that less-frequent 
cervical cancer screening (defined as ordering <1 Pap test per week) was 
associated with over-screening only in women <21 years of age [8]. 
 The strengths of our study are the implementation of a BPA which could 
be monitored prior to being visible to the user, thus allowing pre-intervention and 
post-intervention data to be collected in the same manner. The study was 
conducted over a short period of time, limiting temporal variation in provider 
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practice independent of clinical decision support. All of the data were manually 
reviewed so that indicated Pap tests which triggered the best practice alert were 
coded correctly, decreasing the risk of a type I error. Our study was limited by the 
fact that we could only assess Pap tests which triggered the BPA. Thus, we 
cannot estimate the effect of healthcare provider education through the BPA, 
which would result in the provider not placing an order for a woman in the same 
non-screening group in a future encounter. However, given the similar numbers 
of Pap tests ordered pre- and post-intervention, it is unlikely that this had a 
substantial effect on screening practices. The lack of a difference may also be 
due to suboptimal timing of the BPA. The BPA triggered when the Pap test order 
was placed, and providers may have been reluctant to cancel orders once the 
Pap specimen had been obtained. Additionally, more than 60% of orders were 
placed by staff other than the healthcare provider listed on the clinic encounter, 
and the alert may never have been seen by the provider who ultimately makes 
the cervical cancer screening decision. Although a manual chart review was 
performed, our data collection was limited by the results available within our 
electronic health record system and the providers’ notes. However, coding of Pap 
tests was performed in the same manner and by the same investigators in the 
pre- and post-intervention period, and misclassification of the Pap tests as 
indicated would only strengthen the negative results of our study. Lastly, since 
the effect was measured by proportion of guideline non-adherent Pap tests, and 
a majority of non-adherent Pap tests were ordered by a minority of providers, our 
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study was underpowered to detect practice changes for providers who ordered a 
smaller number of guideline non-adherent Pap tests at baseline. 
 In conclusion, this study showed that clinical decision support within the 
EHR did not improve adherence to national guidelines recommending against 
screening in women <21 years of age, >65 years of age, or post-hysterectomy. 
These results suggest continued over-screening in women beyond the screening 
age limits or post-hysterectomy is due to factors other than lack of knowledge of 
the guidelines at this time. However, this study did not test the impact of clinical 
decision support in women age 21-65 years of age where screening decisions 
are more difficult due to different recommended screening intervals depending on 
the method of screening (cytology alone vs. cytology + HPV co-testing) and 
previous screening results. Thus, electronic health record clinical decision 
support may be useful following the introduction of the next set of guidelines 
which are likely to become more complicated as additional methods of screening 
(primary cytology; primary HPV testing; co-testing), additional diagnostic tests 
(e.g. immunohistochemistry for the p16 tumor suppressor protein), and stratified 
screening recommendations by HPV vaccination status are incorporated.                                                                                                                                                                                                                                                                                                                                                                                                                                                 
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